logo

Clinical Trial Results

Share

walmartpharmacy jun04 31mar20 Akero Therapeutics Inc.'s (AKRO) phase IIa study of its investigational drug AKR-001 in patients with biopsy-confirmed nonalcoholic steatohepatitis, or NASH, has met the primary endpoint.

Axsome Therapeutics Inc. (AXSM) said that the STRIDE-1 Phase 3 Trial did not reach statistical significance on the Week 6 primary endpoint on the Montgomery-Åsberg Depression Rating Scale or MADRS. The trial evaluated the company's AXS-05, an NMDA receptor antagonist with multimodal activity. But,...

Novavax Inc. (NVAX), a late-stage biotechnology company developing vaccines for serious infectious diseases, announced Tuesday positive top-line results of its pivotal Phase 3 clinical trial of NanoFlu. In pre-market activity on Nasdaq, Novavax shares were gaining around 37.08 percent at $14.75. In...

coronavirus feb18 18mar20 Is there a relationship between blood type and susceptibility to COVID-19?

Johnson and Johnson (JNJ) has revealed that there is no evidence to support the use of Darunavir for the treatment of COVID-19. There have been anecdotal, unsubstantiated reports claiming that Darunavir has antiviral effects against the novel coronavirus.

AstraZeneca plc (AZN.L, AZN) said that a final analysis of the Phase III CASPIAN trial showed the company's Imfinzi or durvalumab in combination with a choice of standard-of-care chemotherapies confirmed a sustained, clinically meaningful overall survival benefit for patients with extensive-stage small...

stockinupward march12 As the novel coronavirus COVID-19 continues to spread quickly and severely around the world, pharma companies are racing to find a treatment for the deadly virus.

(Correction: The original headline incorrectly stated that the study met its primary endpoint.) Takeda Pharmaceutical Co. Ltd. (TAK, TKPYY.PK) announced Tuesday the results from the TOURMALINE-MM2 study designed to evaluate the addition of NINLARO (ixazomib) to lenalidomide and dexamethasone in newly...

AstraZeneca plc (AZN.L, AZN) said the Phase III DANUBE trial for Imfinzi and Imfinzi plus tremelimumab in metastatic bladder cancer did not meet primary endpoints. The company said safety and tolerability profiles for Imfinzi and the combination with tremelimumab were consistent with previous trials....

Follow RTT
>